Showing posts with label Announces. Show all posts
Showing posts with label Announces. Show all posts

Sunday, April 10, 2011

InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Cataract Surgery

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8758.

Main Category: Eye Health / Blindness
Also Included In: Pain / Anesthetics
Article Date: 23 Mar 2011 - 9:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
InSite Vision Incorporated (OTCBB:INSV) announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. This randomized four-arm study compared once- and twice-daily doses of ISV-303 versus Xibrom™ and DuraSite® (vehicle), each administered twice-daily. ISV-303 combines a lower dose (0.075%) of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAY™/Xibrom (bromfenac ophthalmic solution) 0.09%, marketed by ISTA Pharmaceuticals) with InSite Vision's proprietary DuraSite drug delivery technology.

The Phase 1/2 clinical trial enrolled 169 patients undergoing cataract surgery. The primary endpoint of the study was the absence of cells in the anterior chamber of the eye at day 15 post surgery. Once-daily ISV-303 achieved statistically significant superiority compared to vehicle (53.3% vs. 19.0%, p=0.0016) for the primary endpoint. Further, secondary endpoints such as reduction of flare, pain and discomfort as a result of inflammation, achieved statistically significant superiority at days 8, 15 and 29 as compared with vehicle. While once-daily ISV-303 achieved a numerically superior difference in the primary endpoint versus twice-daily Xibrom (53.3% vs. 42.2%), the results did not reach statistical significance given the relatively small size of the trial. ISV-303, Xibrom and vehicle were all generally well tolerated and there were no safety concerns or serious adverse events related to any of the agents. InSite Vision intends to present a final analysis of the ISV-303 Phase 1/2 clinical trial in conjunction with a future scientific meeting.

The exploratory Phase 1/2 study was not designed to achieve statistically significant difference between the arms. Nevertheless, the results of this relatively small study comfortably demonstrate the clear efficacy and safety of once-daily ISV-303 over DuraSite in terms of a regulatory pathway, and the promise of a commercially superior once-daily NSAID for post-surgical use in the marketplace. Following final analysis, the Company plans to initiate discussions with the U.S. Food and Drug Administration (FDA) on the design of the pivotal Phase 3 program for once-daily ISV-303. The Company also plans to conduct a Phase 2 pharmacokinetic study of once-daily ISV-303 against ISTA Pharmaceutical's currently marketed once-daily NSAID, BROMDAY.

"It is a delightfully rare situation to experience such stunningly statistically significant results in an exploratory Phase 1/2 study," said Timothy Ruane, Chief Executive Officer of InSite Vision. "With the efficacy and safety profile established in this study, and potential patent protection extending to 2029, we believe once-daily ISV-303 is very well positioned to compete in the growing $300 million ophthalmic NSAID market in the United States. Importantly, the results of this study further transform InSite Vision into a late-stage company with three Phase 3 candidates that we intend to move toward approval."

InSite Vision is advancing another product candidate that utilizes a low-concentration of bromfenac enabled by DuraSite. ISV-101, a lower dose of bromfenac in DuraSite, is being developed for the treatment of dry eye disease. On January 11, 2011, InSite Vision announced it had filed an Investigational New Drug (IND) application for ISV-101 with the FDA. The Company is now positioned to initiate a dose-ranging Phase 1/2 clinical trial in 2011 to evaluate the safety and efficacy of ISV-101 when administered to patients suffering from dry eye disease. Patent protection for this drug candidate is also expected to extend into 2029. Preclinical data on the safety of ISV-303 and ISV-101 (bromfenac formulated in DuraSite) on ocular tissues have been accepted for presentation at the 2011 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1 - 5, 2011 in Fort Lauderdale, Florida.

Cataract surgery is the most frequently performed ocular surgery in the United States with more than three million procedures annually. Following surgery, anti-inflammatory eye drops are typically prescribed to reduce pain and inflammation and to enhance healing.

Dry eye disease occurs when the surface of the eye becomes compromised for various reasons, frequently involving tear-film changes. While causes of dry eye may vary, it is frequently associated with inflammation of the surface of the eye, the lacrimal gland, and/or the conjunctiva. A potentially chronic condition that can occur at any age, dry eye disease is most prevalent among the elderly. It is estimated to affect at least twenty-five million people in the U.S. alone.

About DuraSite®

InSite's DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. InSite vision is also applying DuraSite to multiple other clinical- and preclinical-stage product candidates to create a portfolio of novel ophthalmic products.

Source:
InSite Vision

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Merck Announces FDA Acceptance Of New Drug Application For Investigational Ophthalmic Medication SAFLUTAN(R) (Tafluprost)


Main Category: Eye Health / Blindness
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 13 Mar 2011 - 0:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet rated2 stars
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the New Drug Application (NDA) for SAFLUTAN® (tafluprost), Merck's investigational preservative-free prostaglandin analogue ophthalmic solution, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). SAFLUTAN is the proposed trade name for tafluprost in the United States.

Merck submitted an NDA to support the proposed use of SAFLUTAN for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. SAFLUTAN is believed to help increase the fluid drainage that occurs through the root of the iris in the eye (this fluid is also known as aqueous humor). SAFLUTAN is currently approved in several European countries, including the United Kingdom, Spain and Italy. Additional launches in other countries are expected, pending regulatory approvals.

"Merck has been providing new therapies to help treat eye diseases for more than 50 years," said Joseph Markoff, Ph.D., M.D., global director, Scientific Affairs, Ophthalmology, Merck. "The acceptance of the NDA submission for tafluprost is an important milestone in our effort to bring forward an additional therapeutic option for patients with primary open-angle glaucoma or ocular hypertension."

On April 15, 2009, Merck and Santen Pharmaceutical Co., Ltd. entered into a worldwide licensing agreement for tafluprost. Merck has exclusive commercial rights to tafluprost in Western Europe (excluding Germany), North America, South America, Africa, the Middle East, India and Australia. Santen retains commercial rights to tafluprost in most countries in Eastern Europe, northern Europe and in countries in the Asia Pacific region, including Japan. Santen will have the option to co-promote SAFLUTAN in the United States, if approved.

Source:
Merck

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Tuesday, March 29, 2011

Building Healthy Communities: Los Angeles Region Announces Early Success In Health Care Enrollment


Main Category: Health Insurance / Medical Insurance
Also Included In: Pediatrics / Children's Health
Article Date: 21 Mar 2011 - 4:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
5 starsnot yet rated
Building Healthy Communities: Los Angeles Region announced today the successful enrollment of nearly 100 families into no-cost and low-cost health coverage programs including, Medi-Cal and the state's children health insurance program Healthy Families.

"Which is why we are using the lessons we learn from events like these to inform policy makers of the successes, as well as the barriers, these families are facing throughout the process."

"We are proud of the resources we were able to provide to so many families in just one day," said Charles Fields, Los Angeles Region Program Manager for The California Endowment. "Our successes today illustrate the importance of partnerships within a community. Only by working together can we really make a difference in the health of our children."

The health care enrollment events marked the launch of a series of more than 20 health insurance enrollment fairs starting today and continuing through April 18 in collaboration with Neighborhood Legal Services of Los Angeles County in observation of the one-year anniversary of the Patient Protection and Affordable Care Act. This is the first time the Building Healthy Communities of Long Beach, Boyle Heights and South Los Angeles have joined together in a regional partnership.

Today's enrollment fairs and the month long series of enrollment events are helping Californians like Los Angeles resident Patty Trujillo.

Trujillo has three children under the age of 13 and is unemployed, as is her husband. Fortunately, the family discovered they were eligible for and enrolled in Medi-Cal. For Trujillo, having her family properly covered by Medi-Cal means that if one of her children is in need of emergency services, they will receive the critical medical support necessary, while not incurring exorbitant medical bills, especially during emergency services. Furthermore, having health coverage means she can access preventive care to help keep her family healthy.

"As a parent, I understand the importance of providing health care for our children," said Trujillo who was expecting at the time her family lost medical coverage. "But I also understand how complicated it can be, which I why I am so thankful that there are organizations willing to help families like mine receive the coverage and resources available to us."

"We anticipate that many more families will become eligible for health care in 2014," said Barbara Siegel of Neighborhood Legal Services of Los Angeles County. "Which is why we are using the lessons we learn from events like these to inform policy makers of the successes, as well as the barriers, these families are facing throughout the process."

About Building Healthy Communities

Building Healthy Communities is a 10-year, $1 billion plan of The California Endowment. In connection with staff-led, statewide policy initiatives, 14 communities, including South Los Angeles, Boyle Heights and Long Beach, are taking action to make where they live healthier. They're doing this by improving employment opportunities, education, housing, neighborhood safety, unhealthy environmental conditions, access to healthy food and more. The goal: to create places where children are healthy, safe and ready to learn. Ultimately, we're aiming at nothing less than a transformation in the way all of us think about and support health for all Californians.

Source:
The California Endowment
Neighborhood Legal Services of Los Angeles County

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Monday, March 28, 2011

Covidien Announces FDA Advisory Committee Unanimously Recommends Approval For Pipeline(TM) Embolization Device


Main Category: Vascular
Also Included In: Medical Devices / Diagnostics
Article Date: 21 Mar 2011 - 3:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
Covidien (NYSE:COV), a leading global provider of healthcare products, announced that the U.S. Food and Drug Administration (FDA) Neurological Devices Advisory Panel voted to recommend approval for Pipeline(TM) Embolization Device, intended for the endovascular treatment of large or giant wide-necked intracranial aneurysms in the cavernous and paraclinoid regions of the internal carotid artery.

Pipeline is a new class of embolization device designed to divert blood flow away from the aneurysm in order to provide a complete and durable aneurysm embolization while maintaining patency of the parent vessel.

At its meeting today, the FDA Advisory Panel discussed the Premarket Approval (PMA) application for the Pipeline Embolization Device. Following its review of the PMA data, the Panel voted unanimously to recommend approval. Although the FDA is not required to follow Panel recommendations, it often does.

The Pipeline Embolization Device PMA application is based on the results of the PUFS (Pipeline for Uncoilable or Failed AneurysmS) clinical study that included safety and efficacy data on 108 patients. PUFS is a single-arm study of large and giant, wide-neck or fusiform aneurysms typically not coilable, with six-month safety and effectiveness endpoints.

"Safe and effective treatment of large and giant, wide-neck or non-saccular aneurysms remains a significant unmet clinical need," said Aaron Berez, M.D., General Manager, Neurovascular, Covidien. "Clinical experience suggests that the Pipeline Embolization Device may represent a valuable alternative to current endovascular or surgical treatment options for these types of aneurysms."

"The Pipeline Embolization Device represents a breakthrough endovascular treatment for large, giant and wide-neck aneurysms that are very difficult or impossible to treat with existing therapies such as surgery or coiling," said Joe Woody, President, Vascular Therapies, Covidien. "We believe strongly that the PMA data that was submitted from the PUFS clinical study supports the safety and efficacy of this device."

The Pipeline Embolization Device has received CE Mark approval in Europe and has been sold outside the United States since July 2009.

Source:
Covidien

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Tuesday, March 22, 2011

Curis Announces Positive Results In Genentech Pivotal Phase II Clinical Trial Of GDC-0449 In Advanced Basal Cell Carcinoma


Main Category: Cancer / Oncology
Also Included In: Clinical Trials / Drug Trials
Article Date: 21 Mar 2011 - 3:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC). Genentech informed Curis that the study met its primary endpoint of achieving a target overall response rate, showing that GDC-0449 shrank advanced BCC tumors in a pre-defined percentage of people in the study. A preliminary safety assessment showed the most common adverse events were consistent with previous experience with vismodegib. A detailed safety assessment is ongoing. Roche has indicated that it anticipates making at least one regulatory submission in 2011 to seek approval to commercialize GDC-0449.

Genentech plans to submit the data from the clinical trial for presentation at a future medical meeting.

Roche also informed Curis that GDC-0449 (also known as RG3616) now has a generic name approved by the World Health Organization, vismodegib (pronounced vis-mo-DE-jib).

"We are extremely pleased by the highly encouraging outcome of this study, particularly since there is currently no standard of care for patients with this serious disease," said Dan Passeri, Curis President and Chief Executive Officer. "We look forward to Genentech's presentation of the study data in more detail in the near future, and to its planned regulatory submissions for vismodegib."

About the Pivotal Phase II Trial (ERIVANCE BCC/SHH4476g)

ERIVANCE BCC is an international, single-arm, multi-center, two-cohort, open-label Phase II study that enrolled 104 patients with advanced BCC, including metastatic and/or locally advanced BCC, defined as patients whose lesions are not appropriate for surgery, or for whom surgery would result in substantial deformity. Study participants received 150 mg vismodegib once daily until disease progression. The primary endpoint of the study was overall response rate (tumor shrinkage) as assessed by independent reviewers. Secondary endpoints of the study included overall response rate as assessed by study investigators, duration of response, progression-free survival, overall survival and the safety profile. A preliminary safety assessment showed the most common adverse events were muscle spasms, hair loss, altered taste sensation, weight loss, fatigue, nausea, decreased appetite and diarrhea. Serious adverse events were observed, including fatal events. The deaths are being further evaluated, but do not appear to be related to vismodegib.

About Basal Cell Carcinoma

According to the American Cancer Society, BCC is the most common type of skin cancer and accounts for approximately 80 percent of all diagnosed skin cancers. The disease is generally considered curable when the cancer is restricted to a small area of the skin. However, in a small group of people, if the disease is left untreated or does not respond to treatment, the cancer may advance further into the skin, bones or other tissues. In rare cases, BCC may advance or spread to other parts of the body, at which point the disease can become difficult to treat and life-threatening.

About Vismodegib and the Hedgehog Pathway

Vismodegib is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. However, mutations in the pathway that reactivate Hedgehog signaling are seen in several different types of cancer. Abnormal signaling in the Hedgehog pathway is implicated in the majority of BCC cases.

Genentech is also evaluating vismodegib in a Phase II trial in people with operable forms of BCC, which opened in October 2010. Additionally, vismodegib is being evaluated by third-party investigators in a number of other cancers and in people with BCC who have Gorlin syndrome. Gorlin syndrome is a condition that affects many areas of the body and increases the risk of developing BCC.

Source:
Curis, Inc.


Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here